S&P 500 rides Apple-led tech rally higher
SAN DIEGO—Onyia Jude, the Chief Scientific Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company with a "GREAT" financial health rating according to InvestingPro, recently sold 126 shares of the company’s common stock, amounting to a total of $19,273. The shares were sold at a weighted average price of $152.97 per share, with the transactions occurring at prices ranging from $151.99 to $154.11. This sale was executed under a pre-established Rule 10b5-1 trading plan, with the stock currently trading near its 52-week high of $157.98.
Additionally, Jude acquired 238 shares through the exercise of Restricted Stock Units (RSUs), which were granted as part of a vesting schedule. Following these transactions, Jude directly owns 15,561 shares of Neurocrine Biosciences common stock. The company, which has shown impressive revenue growth of 25.7% over the last twelve months, is scheduled to report earnings in two days. Discover more detailed insights and 14 additional ProTips with InvestingPro.
In other recent news, Neurocrine Biosciences has been the subject of several analyst reports and has also announced significant developments in its product pipeline. Stifel analysts maintained a positive outlook on Neurocrine Biosciences, keeping their price target steady at $166.00. This comes after Neurocrine announced an amendment to their partnership with Takeda, gaining full worldwide development and commercialization rights for the AMPA program, excluding Japan.
Concurrently, Neurocrine sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism, focusing on classic congenital adrenal hyperplasia (CAH), a rare genetic condition. This supplement features eight review articles that delve into the multifaceted challenges faced by individuals with classic CAH.
On the analyst front, Oppenheimer reiterated its Outperform rating for Neurocrine Biosciences, keeping the price target at $192.00. The firm’s analysts highlighted the recent FDA approval of Crenessity for the treatment of CAH as a pivotal event. Furthermore, Piper Sandler maintained an Overweight stock rating for Neurocrine Biosciences, with a price target of $160.00, expressing confidence in the company’s newly launched drug Crenessity.
Lastly, Neurocrine Biosciences published a narrative review in Expert Review of Endocrinology & Metabolism about the challenges of treating CAH with traditional glucocorticoids and the promise of new non-GC therapies. These are the recent developments for Neurocrine Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.